Gurary v. Nu-Tech Bio-Med

303 F.3d 212, 53 Fed. R. Serv. 3d 1292, 2002 U.S. App. LEXIS 17628
CourtCourt of Appeals for the Second Circuit
DecidedAugust 23, 2002
Docket01-7969
StatusPublished

This text of 303 F.3d 212 (Gurary v. Nu-Tech Bio-Med) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gurary v. Nu-Tech Bio-Med, 303 F.3d 212, 53 Fed. R. Serv. 3d 1292, 2002 U.S. App. LEXIS 17628 (2d Cir. 2002).

Opinion

303 F.3d 212

Mordechai GURARY, Plaintiff-Appellant-Cross-Appellee,
v.
NU-TECH BIO-MED, INC., Defendant-Appellee-Cross-Appellant,
Isaac Winehouse, d/b/a Wall & Broad Equities, Defendant.

Docket No. 01-7969(L).

Docket No. 01-9000(XAP).

United States Court of Appeals, Second Circuit.

Argued: May 16, 2002.

Decided: August 23, 2002.

COPYRIGHT MATERIAL OMITTED COPYRIGHT MATERIAL OMITTED Robert J. Tolchin, Jaroslawicz & Jaros, New York, NY, for Plaintiff-Appellant-Cross-Appellee.

Martin E. Karlinsky, Rosenman & Colin, LLP, New York, NY, for Defendant-Appellee-Cross-Appellant.

Before: WALKER, WINTER, and CALABRESI, Circuit Judges.

Chief Judge JOHN M. WALKER, Jr., concurs in a separate opinion.

CALABRESI, Circuit Judge.

Responding to what it perceived to be an unwillingness on the part of courts to impose discretionary sanctions on parties who brought abusive securities fraud lawsuits, Congress passed Section 21D(c) of the Private Securities Litigation Reform Act of 1995 (PSLRA), 15 U.S.C. § 78u-4(c). See S.Rep. No. 104-98, at 13 (1995), reprinted in 1995 U.S.C.C.A.N. 679, 692. While the mischief that Congress was addressing is clear, the statutory language Congress employed is not.

The PSLRA dictates sanctions for frivolous securities fraud complaints and emphasizes the need not only to deter such abusive lawsuits, but also to compensate fully victims of this kind of abusive litigation. It requires district courts overseeing securities fraud suits to make specific findings, upon final adjudication of the action, as to whether all parties and all attorneys have complied with each requirement of Rule 11(b) of the Federal Rules of Civil Procedure. § 78u-4(c)(1). If the court determines that a violation has occurred, the imposition of sanctions is mandatory. § 78u-4(c)(2). The PSLRA further establishes a presumption that, "for substantial failure of any complaint to comply with any requirement" of Rule 11(b), the award shall be the full amount of the reasonable attorneys' fees and costs.1 § 78u-4(c)(3)(A) (emphasis added). Under the statute, this presumption may be rebutted only upon proof that "the violation of [Rule 11(b)] was de minimis" or that the sanctions "will impose an unreasonable burden on that party or attorney and would be unjust, and the failure to make such an award would not impose a greater burden on the party in whose favor sanctions are to be imposed." § 78u-4(c)(3)(B).

On their own terms these provisions present problems. Thus, one might well read the requirement that the violation be a "substantial failure," for purposes of applying the presumption of an award of full fees and costs, to mean that the violation must not be de minimis. But such a reading would make hash of the statute's subsequent provision that a party may rebut this presumption by showing that the violation was de minimis. We must, therefore, read the requirement of a "substantial failure" to mean something else. But what? The matter is made more complex by the fact that the words "substantial failure" and "de minimis" give no guidance as to the proper extent of mandated sanctions when frivolous counts or allegations are part of a suit in which some of the other counts or allegations are not only not frivolous, but may actually have merit. The present case requires us to address these matters.

Attorney David Jaroslawicz and his law firm, Jaroslawicz & Jaros, appeal a judgment from the United States District Court for the Southern District of New York (Stanton, J.), imposing sanctions on Jaroslawicz and his law firm pursuant to Rule 11(b) and § 21D(c) of the PSLRA in the amount of $62,556.28, or approximately one-half of defendant Nu-Tech's costs and attorneys' fees. The sanctions arose out of an action brought by Gurary, a purchaser of common stock in Nu-Tech, in which Gurary alleged securities fraud violations by Nu-Tech and Isaac Winehouse. Gurary claimed that Winehouse was the leader of a "cartel" that purchased convertible preferred stock and manipulated stock prices by short selling in violation of Section 10b of the Securities Exchange Act of 1934, 15 U.S.C. § 78j, and 17 C.F.R. § 240.10b-5 ("Rule 10b-5"), as well as § 349 of the General Business Law of the State of New York. According to Gurary's various theories of recovery, Nu-Tech knew of the short selling and committed fraud by concealing material information and providing misinformation in violation of Rule 10b-5.

The district court dismissed the complaint and we affirmed that dismissal. Gurary v. Winehouse ("Gurary I"), 190 F.3d 37 (2d Cir.1999). We subsequently directed the imposition of sanctions with respect to two of Gurary's four claims against Nu-Tech, Gurary v. Winehouse ("Gurary II"), 235 F.3d 792 (2d Cir.2000). On remand, the district court ordered sanctions against attorney Jaroslawicz and his firm in an amount equal to approximately one-half of Nu-Tech's attorneys' fees and costs in the action. Before us, Jaroslawicz challenges several aspects of the district court's sanctions ruling. At the same time, Nu-Tech claims, in a cross-appeal, that the court committed legal error by not imposing sanctions equal to all of Nu-Tech's costs and fees.

Background

In his securities lawsuit, Gurary alleged that in November of 1996 Nu-Tech privately issued 14,000 shares of "Series A Convertible Preferred Stock" for a total price of $14 million. Gurary claimed that Winehouse and his cartel arranged to buy a large part of the Convertible Stock in the name of third parties. The Winehouse cartel then allegedly began selling Nu-Tech common stock short, using various accounts to conceal the identity of its members. It could sell short in relative safety because of its ownership of the Convertible Preferred Stocks. According to Gurary, the cartel's purpose was to manipulate the market and drive down the price of Nu-Tech shares.

In his complaint, Gurary states that on four occasions he purchased shares of Nu-Tech common: (1) 1,000 shares on October 31, 1996, for $14.60 per share; (2) 5,500 shares on November 7, 1996, for $15.50; (3) 1,000 shares on December 24, 1996, for $11.75; and (4) 8,350 shares on February 18, 1997, for $11.57. In December 1996, after Gurary's first two purchases, the stock price began to decline, presumably as a result of the short selling. Gurary further alleges that Marvin Feigenbaum, chairman of Nu-Tech, assured Gurary that Feigenbaum had informed Winehouse that Nu-Tech would refuse to register any stock that would be converted from Convertible Preferred Stock to common stock unless Winehouse stopped shorting the common. Gurary states that he made his third purchase of common stock on December 24, 1996 based upon Feigenbaum's assurances.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Southeastern Community College v. Davis
442 U.S. 397 (Supreme Court, 1979)
K Mart Corp. v. Cartier, Inc.
486 U.S. 281 (Supreme Court, 1988)
Cooter & Gell v. Hartmarx Corp.
496 U.S. 384 (Supreme Court, 1990)
Gurary v. Winehouse
153 F. Supp. 2d 489 (S.D. New York, 2001)
Polar International Brokerage Corp. v. Reeve
120 F. Supp. 2d 267 (S.D. New York, 2000)
Gurary v. Winehouse
190 F.3d 37 (Second Circuit, 1999)
Krumme v. WestPoint Stevens Inc.
238 F.3d 133 (Second Circuit, 2000)
Corroon v. Reeve
258 F.3d 86 (Second Circuit, 2001)
Gurary v. Nu-Tech Bio-Med, Inc.
303 F.3d 212 (Second Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
303 F.3d 212, 53 Fed. R. Serv. 3d 1292, 2002 U.S. App. LEXIS 17628, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gurary-v-nu-tech-bio-med-ca2-2002.